Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Cytosorbents Corp’s stock clocked out at $0.91, up 1.21% from its previous closing price of $0.90. In other words, the price has increased by $1.21 from its previous closing price. On the day, 0.15 million shares were traded. CTSO stock price reached its highest trading level at $0.9501 during the session, while it also had its lowest trading level at $0.9071.
Ratios:
To gain a deeper understanding of CTSO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.58 and its Current Ratio is at 1.97. In the meantime, Its Debt-to-Equity ratio is 2.06 whereas as Long-Term Debt/Eq ratio is at 2.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $4.
On September 17, 2020, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on September 17, 2020, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’23 when Sobel Alan D. bought 22,557 shares for $1.33 per share. The transaction valued at 30,001 led to the insider holds 101,857 shares of the business.
Deliargyris Efthymios bought 22,557 shares of CTSO for $30,001 on Dec 13 ’23. The Chief Medical Officer now owns 348,433 shares after completing the transaction at $1.33 per share. On Dec 13 ’23, another insider, Capponi Vincent, who serves as the President & COO of the company, bought 18,797 shares for $1.33 each. As a result, the insider paid 25,000 and bolstered with 584,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTSO now has a Market Capitalization of 49769372 and an Enterprise Value of 70890744. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.32 while its Price-to-Book (P/B) ratio in mrq is 3.82. Its current Enterprise Value per Revenue stands at 1.878 whereas that against EBITDA is -3.593.
Stock Price History:
Over the past 52 weeks, CTSO has reached a high of $2.15, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is -16.34%, while the 200-Day Moving Average is calculated to be -7.81%.
Shares Statistics:
It appears that CTSO traded 115.02K shares on average per day over the past three months and 109900 shares per day over the past ten days. A total of 54.24M shares are outstanding, with a floating share count of 46.76M. Insiders hold about 14.48% of the company’s shares, while institutions hold 31.15% stake in the company. Shares short for CTSO as of 1731628800 were 1298947 with a Short Ratio of 11.29, compared to 1728950400 on 1348703. Therefore, it implies a Short% of Shares Outstanding of 1298947 and a Short% of Float of 2.4400001000000002.
